Gerald W. Prager

Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial

Vivek Subbiah, Ulrik Lassen, Élena Elez et al. · The Lancet Oncology · 2020 · 518 citations

Medicine, Oncology, Pharmacology +11

Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Thierry Conroy, Per Pfeiffer, Valérie Vilgrain et al. · Annals of Oncology · 2023 · 511 citations · Full text

Medicine, Oncology, Surgery +14

Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer

Gerald W. Prager, Marwan Fakih, Fortunato Ciardiello et al. · New England Journal of Medicine · 2023 · 428 citations · Full text

Medicine, Oncology, Pharmacotherapy +11

uPAR – uPA – PAI-1 interactions and signaling: A vascular biologist’s view

Judit Mihaly, Gerald W. Prager, Bernd R. Binder · Thrombosis and Haemostasis · 2007 · 231 citations

Life Sciences, Cell Biology, Molecular Biology +17

Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders

Christoph Kornauth, Tea Pemovska, Gregory I. Vladimer et al. · Cancer Discovery · 2021 · 207 citations · Full text

Medicine, Hematology, Oncology +12